MDT:NYE-Medtronic plc.

EQUITY | Medical Devices | New York Stock Exchange

Last Closing

USD 87.3

Change

0.00 (0.00)%

Market Cap

USD 101.99B

Volume

8.55M

Analyst Target

USD 104.96
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Medtronic PLC is engaged in providing medical technology alleviating pain, restoring health, and extending life of people. It currently functions in four operating segments that manufacture and sell device-based medical therapies.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-01-20 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

-0.63 (-0.59%)

USD 189.50B
SYK Stryker Corporation

-8.58 (-2.55%)

USD 133.55B
BSX Boston Scientific Corp

-0.54 (-0.79%)

USD 100.13B
EW Edwards Lifesciences Corp

-0.79 (-0.91%)

USD 55.80B
ZBH Zimmer Biomet Holdings Inc

-1.97 (-1.62%)

USD 26.16B
STE STERIS plc

+0.57 (+0.28%)

USD 21.09B
PHG Koninklijke Philips NV ADR

-0.17 (-0.84%)

USD 18.20B
SNN Smith & Nephew SNATS Inc

+0.09 (+0.38%)

USD 10.70B
PEN Penumbra Inc

-6.84 (-3.28%)

USD 8.60B
BIO-B Bio-Rad Laboratories Inc

-58.64 (-17.32%)

USD 8.54B

ETFs Containing MDT

CYBG:LSE VanEck Bionic Engineering.. 9.92 % 0.00 %

-0.03 (-0.15%)

USD 6.05M
UMDV:SW iShares US Medical Device.. 9.70 % 0.00 %

-0.03 (-0.15%)

USD 0.18B
CIB0:XETRA VanEck Bionic Engineering.. 9.50 % 0.00 %

-0.16 (-0.15%)

USD 6.36M
PINK Simplify Exchange Traded .. 4.65 % 0.00 %

-0.05 (-0.15%)

USD 0.13B
AIVL WisdomTree Trust - Wisdom.. 3.05 % 0.00 %

+0.20 (+-0.15%)

USD 0.38B
GDVD Principal Active Global D.. 2.46 % 0.00 %

-0.08 (-0.15%)

USD 0.03B
QUVU 2.33 % 0.00 %

N/A

N/A
DXQ:CA Dynamic Active Enhanced Y.. 2.30 % 0.00 %

-0.03 (-0.15%)

CAD 0.38B
DVND Touchstone ETF Trust - To.. 2.19 % 0.00 %

-0.04 (-0.15%)

USD 0.03B
PUD.B:CA 1.85 % 0.66 %

N/A

N/A
TWAR 1.11 % 0.00 %

N/A

N/A
BLV Vanguard Long-Term Bond I.. 0.00 % 0.07 %

-0.28 (-0.15%)

USD 6.22B
DTN 0.00 % 0.38 %

N/A

N/A
IHI iShares U.S. Medical Devi.. 0.00 % 0.43 %

-0.25 (-0.15%)

USD 5.55B
JDIV 0.00 % 0.12 %

N/A

N/A
AIIQ 0.00 % 0.79 %

N/A

N/A
JIGB JPMorgan Corporate Bond R.. 0.00 % 0.14 %

N/A

USD 0.06B
GDNA 0.00 % 0.00 %

N/A

N/A
INAU 0.00 % 0.00 %

N/A

N/A
HWF:CA 0.00 % 0.00 %

N/A

N/A
RXD ProShares UltraShort Heal.. 0.00 % 0.77 %

+0.01 (+-0.15%)

USD 1.09M
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

+0.01 (+-0.15%)

USD 1.09M
SCHZ Schwab U.S. Aggregate Bon.. 0.00 % 0.04 %

-0.10 (-0.15%)

USD 7.53B
SICK 0.00 % 0.95 %

N/A

N/A
VCLT Vanguard Long-Term Corpor.. 0.00 % 0.07 %

-0.20 (-0.15%)

USD 7.80B
VCSH Vanguard Short-Term Corpo.. 0.00 % 0.07 %

-0.06 (-0.15%)

USD 35.77B
YLD Principal Active High Yie.. 0.00 % 0.65 %

N/A

USD 0.17B
XUKS:LSE db x-trackers FTSE 100 Sh.. 0.00 % 0.00 %

-0.85 (-0.15%)

USD 8.61M
OUFH:XETRA 0.00 % 0.00 %

N/A

N/A
ABEQ Absolute Core Strategy ET.. 0.00 % 0.00 %

+0.18 (+-0.15%)

USD 0.08B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.02% 13% F 4% F
Dividend Return N/A N/A N/A N/A F
Total Return -4.02% 13% F 4% F
Trailing 12 Months  
Capital Gain 0.72% 38% F 82% B
Dividend Return 2.26% 100% F 43% F
Total Return 2.98% 38% F 78% C+
Trailing 5 Years  
Capital Gain 46.70% 27% F 83% B
Dividend Return 13.58% 86% B+ 48% F
Total Return 60.28% 27% F 82% B
Average Annual (5 Year Horizon)  
Capital Gain 8.99% 23% F 77% C+
Dividend Return 11.13% 23% F 77% C+
Total Return 2.14% 71% C- 43% F
Risk Return Profile  
Volatility (Standard Deviation) 11.09% 92% A 63% D
Risk Adjusted Return 100.34% 62% D 85% B
Market Capitalization 101.99B 94% A 99% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 31.40 25% 9%
Price/Book Ratio 2.34 87% 33%
Price / Cash Flow Ratio 5.63 44% 18%
Price/Free Cash Flow Ratio 24.32 50% 22%
Management Effectiveness  
Return on Equity 4.50% 44% 36%
Return on Invested Capital 8.68% 56% 50%
Return on Assets 2.48% 56% 49%
Debt to Equity Ratio 52.00% 79% 60%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.